Weary pSivida investors unmoved by positive Phase III trial

14 June 2017

Shares in Massachusetts, USA-based drugmaker pSivida (Nasdaq: PSDV) have fallen over 15% since close of trading on Monday, despite positive news from the company’s second Phase III trial into Durasert for posterior uveitis.

The company, which specializes in sustained release ophthalmic medicines, said the primary endpoint of prevention of recurrence of posterior uveitis at six months, with patients continuing to be followed for 36 months, was met in the study of 153 patients.

Previously known as Medidur, the therapy has been under development for many years in collaboration with USA-based Alimera (Nasdaq: ALIM), but has failed to gain approval from regulators.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK